| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/08/2005 | EP1537106A1 Dihydropyrazolopyridine compounds |
| 06/08/2005 | EP1537099A1 Pyrrole based inhibitors of glycogen synthase kinase 3 |
| 06/08/2005 | EP1537087A1 Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
| 06/08/2005 | EP1537078A1 Indoles having anti-diabetic activity |
| 06/08/2005 | EP1537076A1 Novel vinyl carboxylic acid derivatives and their therapeutical use |
| 06/08/2005 | EP1537074A1 Cathepsin cysteine protease inhibitors |
| 06/08/2005 | EP1537073A2 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 06/08/2005 | EP1537068A1 Materials and methods for treating hypercholesterolemia |
| 06/08/2005 | EP1536837A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 06/08/2005 | EP1536826A2 Thymus-based tolerogenic approaches for type i diabetes. |
| 06/08/2005 | EP1536817A1 Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia |
| 06/08/2005 | EP1536812A2 Methods for modulating activity of the fxr nuclear receptor |
| 06/08/2005 | EP1536805A1 Nutricional compositions comprising a non-glucose carbohydrate or pectin and soluble fiber |
| 06/08/2005 | EP1536801A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 06/08/2005 | EP1536799A1 Novel 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properties |
| 06/08/2005 | EP1536797A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1) antagonsists for the treatment of emesis, depression, anxiety and cough |
| 06/08/2005 | EP1536796A1 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| 06/08/2005 | EP1536778A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/08/2005 | EP1536775A1 Compositions comprising hmg-coa reductase inhibitor |
| 06/08/2005 | EP1536751A2 Use of a genus i halopteris /i brown alga extract in a cosmetic or pharmaceutical composition for limiting adipose tissue expansion and corresponding cosmetic or pharmaceutical composition |
| 06/08/2005 | EP1465854A4 Chalcone derivatives and their use to treat diseases |
| 06/08/2005 | EP1408981A4 Methods for preventing antipsychotic-induced weight gain |
| 06/08/2005 | EP1373269B1 Jun kinase inhibitors |
| 06/08/2005 | EP1370528B1 Mch antagonists and their use in the treatment of obesity |
| 06/08/2005 | EP1309575B1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 06/08/2005 | EP1252133B1 Pharmaceutical compounds |
| 06/08/2005 | EP1240285B1 Stabilisation of pigments and polyunsaturated oils and oil concentrates |
| 06/08/2005 | EP1220831B1 Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| 06/08/2005 | EP1189895B1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 06/08/2005 | CN1625558A Aza-arylpiperazines |
| 06/08/2005 | CN1625554A Amides of aminoalkyl substituted azetidines, pyrrolidines, piperidines and azepanes |
| 06/08/2005 | CN1625404A Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 06/08/2005 | CN1625390A Multi-stage oral drug controlled-release system |
| 06/08/2005 | CN1625385A Lipase inhibiting composition |
| 06/08/2005 | CN1625346A Powder of amino acids and method for producing the same |
| 06/08/2005 | CN1623578A Fat lowering medicine |
| 06/08/2005 | CN1623576A Application of opium seed in medicine for preparing diabetes |
| 06/08/2005 | CN1623566A Kender body fat reducing tea |
| 06/08/2005 | CN1623562A Active calcium and its production method |
| 06/08/2005 | CN1623558A 南瓜多糖肠溶制剂 Pumpkin polysaccharide enteric preparation |
| 06/08/2005 | CN1623557A Application of gold ear mycelium polysaccharide for lowering blood fat and blood sugar |
| 06/08/2005 | CN1623547A Medical use of artificial lywrine |
| 06/08/2005 | CN1205207C Substituted indolealkanoic acids |
| 06/08/2005 | CN1205205C Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 06/08/2005 | CN1205188C 4,5-dihydro-1h-pyrazole derivatives having CB1-antagonistic activity |
| 06/08/2005 | CN1205172C Crystals of sodium salt of pravastatin |
| 06/08/2005 | CN1204923C Anhydrous topical ski preparation |
| 06/08/2005 | CN1204892C Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |
| 06/08/2005 | CN1204885C Pharmaceutical composition contg. fenofibrate and preparation method |
| 06/08/2005 | CN1204884C N-acetyl-L cysteine for preparing medicine for treating epithelial tumous |
| 06/08/2005 | CN1204870C Dental care compositions |
| 06/08/2005 | CN1204821C Denatured sorghum candy and its use |
| 06/07/2005 | US6903215 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 06/07/2005 | US6903186 Analogues of GLP-1 |
| 06/07/2005 | US6903131 Administering to a patient an antiangiogenesis or anticancer agent (N,N-disubstituted-3,4-diamino-2,4-dione-pyrroline derivatives for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer |
| 06/07/2005 | US6903129 D-proline prodrugs |
| 06/07/2005 | US6903128 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 06/07/2005 | US6903120 Modulators of dopamine neurotransmission |
| 06/07/2005 | US6903115 Bipiperidine compounds |
| 06/07/2005 | US6903111 Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same |
| 06/07/2005 | US6903103 Linear cyclic ureas |
| 06/07/2005 | US6903090 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal |
| 06/07/2005 | US6903088 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 06/07/2005 | US6903087 Pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists |
| 06/07/2005 | US6903085 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 06/07/2005 | US6903083 Stabilized hydroxyvitamin D |
| 06/07/2005 | US6903071 Cartilage/bone inducing materials for reparation |
| 06/07/2005 | US6902908 Polypeptides, fusion proteins; includes production and use recombinant expression constructs having regulated promoter; mitochondria |
| 06/07/2005 | US6902748 Medicines manufactured from old platycodon extracts |
| 06/07/2005 | US6902744 Exendin agonist formulations and methods of administration thereof |
| 06/07/2005 | US6902739 Administering a stabilized rice bran derivative and a fortification agent; treating bone disorders |
| 06/07/2005 | CA2051693C Allosteric hemoglobin modifiers |
| 06/02/2005 | WO2005049057A1 Use of cassia sophera linn. for treating diabetes |
| 06/02/2005 | WO2005048738A1 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic |
| 06/02/2005 | WO2005030332A3 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 06/02/2005 | WO2005007845A3 Transgenic cells |
| 06/02/2005 | WO2004112762A3 Pharmaceutical formulations of amyloid inhibiting compounds |
| 06/02/2005 | WO2004105763A3 Use of tyrosine kinase inhibitor to treat diabetes |
| 06/02/2005 | WO2003059253A3 Compositions and methods for altering glucose production |
| 06/02/2005 | US20050119489 Antidiabetic, anorexigenic, hypotensive, and anticholesterol agents that are synergistically combined with other active agents; obesity, premenstrual tension, hyperlipidemia, myocardial infarction and skin disorders |
| 06/02/2005 | US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics |
| 06/02/2005 | US20050119343 Crystalline form; inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase; for oral administration |
| 06/02/2005 | US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor |
| 06/02/2005 | US20050119327 1-benzyl-5-[(3-methylphenyl)amino]-3-phenyl-1H-indole-2-carboxylic acid; plasminogen activator inhibitor (PAI-1) inhibitor; fibrinolytic system disorder; atrial fibrillation, pulmonary and renal fibrosis, Alzheimer's disease; anticarcinogenic, antiischemic, anticoagulant, antidiabetic |
| 06/02/2005 | US20050119321 2-substituted-1,3-thiazole compounds |
| 06/02/2005 | US20050119320 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 06/02/2005 | US20050119305 N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide; hydroxamic acid derivative and equivalent thereof; antiinflammatory, anticarcinogenic, antiarthritic, antidiabetic agents; sepsis, leukemia, osteoporosis, skin disorders, cachexia, autoimmune diseases, hepatitis, endometriosis; hypergammaglobulinemia |
| 06/02/2005 | US20050119280 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives |
| 06/02/2005 | US20050119274 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; |
| 06/02/2005 | US20050119272 amplify the effect of nitric oxide on skeletal muscle insulin-mediated glucose uptake; antidiabetic agents |
| 06/02/2005 | US20050119271 Pyrimidine A2B selective antagonist compounds, their synthesis and use |
| 06/02/2005 | US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2005 | US20050119246 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction |
| 06/02/2005 | US20050119206 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 06/02/2005 | US20050119204 Osteopontin-related compositions and methods |
| 06/02/2005 | US20050119192 Crystals of glucopyranosyloxybenzyl benzene derivative |
| 06/02/2005 | US20050119174 Novel blood sugar controller and method of screening the same |
| 06/02/2005 | US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 06/02/2005 | US20050118579 Using allelic variation in canalicular multispecific organic anion transporter (cMOAT) gene as diagnostic tool in detection of liver and bile duct disorders |
| 06/02/2005 | US20050118290 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |